AU2002355693A1 - Treatment of ocular hypertension and glaucoma - Google Patents
Treatment of ocular hypertension and glaucomaInfo
- Publication number
- AU2002355693A1 AU2002355693A1 AU2002355693A AU2002355693A AU2002355693A1 AU 2002355693 A1 AU2002355693 A1 AU 2002355693A1 AU 2002355693 A AU2002355693 A AU 2002355693A AU 2002355693 A AU2002355693 A AU 2002355693A AU 2002355693 A1 AU2002355693 A1 AU 2002355693A1
- Authority
- AU
- Australia
- Prior art keywords
- keto
- prostaglandin compound
- alkyl
- composition
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010030043 Ocular hypertension Diseases 0.000 title claims description 14
- 208000010412 Glaucoma Diseases 0.000 title claims description 13
- -1 13, 14-dihydro-15-keto- prostaglandin compound Chemical class 0.000 claims description 48
- 125000000217 alkyl group Chemical group 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 32
- 150000001875 compounds Chemical class 0.000 claims description 27
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 22
- 125000003118 aryl group Chemical group 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- 150000002367 halogens Chemical class 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 239000003889 eye drop Substances 0.000 claims description 13
- 125000000623 heterocyclic group Chemical group 0.000 claims description 13
- 125000004043 oxo group Chemical group O=* 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 125000001931 aliphatic group Chemical group 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 229920006395 saturated elastomer Polymers 0.000 claims description 9
- 125000004104 aryloxy group Chemical group 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 150000001721 carbon Chemical group 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 230000004410 intraocular pressure Effects 0.000 description 18
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- 210000000554 iris Anatomy 0.000 description 11
- 229940012356 eye drops Drugs 0.000 description 10
- 230000007794 irritation Effects 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 210000004087 cornea Anatomy 0.000 description 9
- 230000008961 swelling Effects 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 150000005215 alkyl ethers Chemical class 0.000 description 6
- 210000000795 conjunctiva Anatomy 0.000 description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 6
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000003885 eye ointment Substances 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 125000005907 alkyl ester group Chemical group 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102100035194 Placenta growth factor Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 229960001160 latanoprost Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical compound CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229940002639 xalatan Drugs 0.000 description 3
- SZNYYWIUQFZLLT-UHFFFAOYSA-N 2-methyl-1-(2-methylpropoxy)propane Chemical compound CC(C)COCC(C)C SZNYYWIUQFZLLT-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 206010010726 Conjunctival oedema Diseases 0.000 description 2
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 150000002373 hemiacetals Chemical class 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- DZUXGQBLFALXCR-UHFFFAOYSA-N (+)-(9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprost-13-en-1-oic acid Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CCCCCCC(O)=O DZUXGQBLFALXCR-UHFFFAOYSA-N 0.000 description 1
- PNKZBZPLRKCVLI-UHFFFAOYSA-N (2-methylpropan-2-yl)oxybenzene Chemical compound CC(C)(C)OC1=CC=CC=C1 PNKZBZPLRKCVLI-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- NKJOXAZJBOMXID-UHFFFAOYSA-N 1,1'-Oxybisoctane Chemical compound CCCCCCCCOCCCCCCCC NKJOXAZJBOMXID-UHFFFAOYSA-N 0.000 description 1
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical class CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- POEDHWVTLBLWDA-UHFFFAOYSA-N 1-butylindole-2,3-dione Chemical compound C1=CC=C2N(CCCC)C(=O)C(=O)C2=C1 POEDHWVTLBLWDA-UHFFFAOYSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- DEBGMRXCXCOKTA-UHFFFAOYSA-N 1-methoxy-1-(1-methoxyethoxy)ethane Chemical compound COC(C)OC(C)OC DEBGMRXCXCOKTA-UHFFFAOYSA-N 0.000 description 1
- UXPPDBVMSPAPCL-UHFFFAOYSA-N 1-prop-1-ynoxyprop-1-yne Chemical compound CC#COC#CC UXPPDBVMSPAPCL-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PRHCBRXAHBBRKA-UHFFFAOYSA-N 2-(2-hydroxypropan-2-yloxy)propan-2-ol Chemical compound CC(C)(O)OC(C)(C)O PRHCBRXAHBBRKA-UHFFFAOYSA-N 0.000 description 1
- PLNNBRYFKARCEV-UHFFFAOYSA-N 2-[(2-hydroxyphenyl)methoxymethyl]phenol Chemical compound OC1=CC=CC=C1COCC1=CC=CC=C1O PLNNBRYFKARCEV-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- SAWMBRUFQYQNLJ-UHFFFAOYSA-N 3-ethyl-3-(3-ethyloctan-3-yloxy)octane Chemical compound CCCCCC(CC)(CC)OC(CC)(CC)CCCCC SAWMBRUFQYQNLJ-UHFFFAOYSA-N 0.000 description 1
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 1
- XHWSCQCJAPLELI-UHFFFAOYSA-N 4-(3,4-dimethoxyphenoxy)-1,2-dimethoxybenzene Chemical compound C1=C(OC)C(OC)=CC=C1OC1=CC=C(OC)C(OC)=C1 XHWSCQCJAPLELI-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 231100000635 Draize test Toxicity 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010018307 Glaucoma and ocular hypertension Diseases 0.000 description 1
- 102100031132 Glucose-6-phosphate isomerase Human genes 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101150020741 Hpgds gene Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- QUXMPZUVBXHUII-UHFFFAOYSA-N [1,1-bis(hydroxymethylamino)ethylamino]methanol Chemical class OCNC(C)(NCO)NCO QUXMPZUVBXHUII-UHFFFAOYSA-N 0.000 description 1
- PVQATPQSBYNMGE-UHFFFAOYSA-N [benzhydryloxy(phenyl)methyl]benzene Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)OC(C=1C=CC=CC=1)C1=CC=CC=C1 PVQATPQSBYNMGE-UHFFFAOYSA-N 0.000 description 1
- XXFXTBNFFMQVKJ-UHFFFAOYSA-N [diphenyl(trityloxy)methyl]benzene Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)OC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 XXFXTBNFFMQVKJ-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000003931 anilides Chemical class 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 150000003939 benzylamines Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 150000003946 cyclohexylamines Chemical class 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- UZBQIPPOMKBLAS-UHFFFAOYSA-N diethylazanide Chemical compound CC[N-]CC UZBQIPPOMKBLAS-UHFFFAOYSA-N 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 150000004656 dimethylamines Chemical class 0.000 description 1
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical compound CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- LZTCEQQSARXBHE-UHFFFAOYSA-N ethoxycyclopropane Chemical compound CCOC1CC1 LZTCEQQSARXBHE-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- CQYBANOHCYKAEE-UHFFFAOYSA-N ethynoxyethyne Chemical compound C#COC#C CQYBANOHCYKAEE-UHFFFAOYSA-N 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- HNPFPERDNWXAGS-NFVOFSAMSA-N latanoprost free acid Chemical compound C([C@@H](O)CCC=1C=CC=CC=1)C[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O HNPFPERDNWXAGS-NFVOFSAMSA-N 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- NSPJNIDYTSSIIY-UHFFFAOYSA-N methoxy(methoxymethoxy)methane Chemical compound COCOCOC NSPJNIDYTSSIIY-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 150000003956 methylamines Chemical class 0.000 description 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- AIAKLPAJNLBVEA-UHFFFAOYSA-N n-[2-(2-benzamidophenoxy)phenyl]benzamide Chemical compound C=1C=CC=CC=1C(=O)NC1=CC=CC=C1OC1=CC=CC=C1NC(=O)C1=CC=CC=C1 AIAKLPAJNLBVEA-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 210000000826 nictitating membrane Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 208000013441 ocular lesion Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003822 preparative gas chromatography Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- CBOMORHDRONZRN-QLOYDKTKSA-N prostaglandin E3 Chemical compound CC\C=C/C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O CBOMORHDRONZRN-QLOYDKTKSA-N 0.000 description 1
- SAKGBZWJAIABSY-SAMSIYEGSA-N prostaglandin F3alpha Chemical compound CC\C=C/C[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O SAKGBZWJAIABSY-SAMSIYEGSA-N 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N trimethylxanthine Natural products CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229920001567 vinyl ester resin Polymers 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
Description
DESCRIPTION
METHOD AND COMPOSITION FOR TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA TECHNICAL FIELD
The present invention relates to a method for treating ocular hypertension and glaucoma, which causes reduced or substantially no ocular irritation such as conjunctival hyperemia. The present invention also provides a composition useful for treatment of the present invention. BACKGROUND ART
Prostaglandins (hereinafter referred to as PG(s)) are the members of class of organic carboxylic acids that are contained in the tissues or organs of humans or other mammals and exhibit a wide range of physiological activity. PGs found in nature (primary PGs) generally have a prostanoic acid skeleton as shown in the formula (A) :
( chain)
On the other hand, some of synthetic analogues of primary PGs have modified skeletons. The primary PGs are classified to PGAs, PGBs, PGCs, PGDs, PGEs, PGFs, PGGs, PGHs, PGIs and PGJs
according to the structure of the five-membered ring moiety, and further classified into the following three types by the number and position of the unsaturated bond at the carbon chain moiety: Subscript 1: 13, 14-unsaturated-15-OH
Subscript 2: 5,6- and 13, 14-diunsaturated-15-OH
Subscript 3: 5,6-, 13,14-, and 17, 18-triunsaturated-15-OH.
Further, the PGFs are classified, according to the configuration of the hydroxyl group at the 9-position, into type (the hydroxyl group is of an -configuration) and β type
(the hydroxyl group is of a β-configuration) .
PGE-L, PGE2 and PGE3 are known to have vasodilation, hypotension, gastric secretion decreasing, intestinal tract movement enhancement, uterine contraction, diuretic, bronchodilation and anti ulcer activities. PGFlα, PGF2αand PGF3α have been known to have hypertension, vasoconstriction, intestinal tract movement enhancement, uterine contraction, lutein body atrophy and bronchoconstriction activities.
Some 15-keto (i.e., having oxo at the 15-position instead of hydroxy) -PGs and 13, 14-dihydro-15-keto-PGs are known as the substances naturally produced by the action of enzymes during the metabolism of primary PGs. It is also known that some 15-keto-PG compounds have intraocular pressure reducing effects and are effective for the treatment of ocular hypertension and g'laucoma (U.S. Patent Nos. 5,001,153,
5,151,444, 5,166,178 and 5,212,200, all of which are incorporated herein by reference) .
Meanwhile, "Xalatan®" that has been launched as an eye drops for ocular hypertension and glaucoma contains, as an active ingredient thereof, latanoprost, i.e., 13,14- dihydro-17-phenyl-18, 19, 20-trinor-PGF2 a isopropyl ester, which is a prostaglandin derivative having a ring structure at the end of the ω chain and having hydroxy at the 15-position. The clinical concentration of latanoprost in the "Xalatan®" eye drops is 0.005% and, estimating from about 30-35μl of one drop volume of "Xalatan eye drops, the clinical dose of latanoprost is about 1.5μg-l .75μg per eye per administration . Problematic side effects of this eye drops in clinically applied dose, including iris pigmentation, ocular irritation such as conjunctival hyperemia and chemosis of conjunctiva have been reported (American Journal of Ophthalmology 2001; 131: 631- 635, Survey of Ophthalmology 1997; 41: S105-S110, the cited references are herein incorporated by reference) .
It is known that a 15-keto-prostaglandin compound having a ring structure at the end of the ω chain has intraocular pressure reducing effects. U.S. Patent No. 5,321,128 describes that administration of 13, 14-dihydro-15-keto- 17- phenyl-18, 19, 20-trinor-PGF2α isopropyl ester to healthy human eyes and monkey eyes in a dose of 5μg and 3μg, respectively, showed intraocular pressure reducing effects, and showed no
side effect such as conjunctival hyperemia, ocular irritation and foreign body sensation in the human. There is another document reporting that administration of 13, 14-dihydro-15- keto-17-phenyl-18, 19, 20-trinor-PGF2α isopropyl ester to monkey eyes (50μg per eye) showed intraocular pressure reducing effects (Clinical Report Vol. 28, No. 11, pages 3505-3509, 1994).
However, in the treatment of ocular hypertension and glaucoma, nobody has known the extent of ocular irritation such as conjunctival hyperemia shown in the administration of a 15-keto-prostaglandin compound having a ring structure at the end of the ω chain to mammal eyes in a high dose. DISCLOSURE OF THE INVENTION
The present inventor has conducted intensive studies on the biological activity of a 15-keto-prostaglandin compound having a ring structure at the end of the ω chain, and found that administration of said compound topically to mammal eyes effectively lowered the intraocular pressure while causes substantially no or reduced ocular irritation such as conjunctival hyperemia, even in a high dose.
Namely, the present invention relates to a method for treatment of ocular hypertension and glaucoma, which comprises administrating a 15-keto-prostaglandin compound having a ring structure at the end of the ω chain topically to the eyes of a mammalian subject in need of such treatment more than 5μg and
less than 50μg per eye per administration. According to the present invention, intra ocular pressure of the subject is effectively lowered while substantially no or reduced ocular irritation, such as conjunctival hyperemia, is observed despite of the high dose.
The present invention further relates to an ophthalmic composition for treating ocular hypertension and glaucoma of a mammalian subject, which comprises a 15-keto-prostaglandin compound having a ring structure at the end of the ω chain in an amount to provide a dose of more than 5μg and less than 50μg per eye per administration.
The present invention further relates to use of a 15-keto-prostaglandin compound having a ring structure at the end of the ω chain for manufacturing an ophthalmic composition for treating ocular hypertension and glaucoma of a mammalian subject, wherein said composition comprises the 15-keto- prostaglandin compound in an amount to provide a dose of more than 5μg and less than 50μg per eye per administration.
In the present invention, the "15-keto-prostaglandin compound" (hereinafter, referred to as "15-keto-PG compound") may include any of derivatives or analogs (including substituted derivatives) of a compound having an oxo group at 15-position of the prostanoic acid skeleton instead of the hydroxy group, irrespective of the configuration of the five-membered ring, "the number of double bonds, presence or
absence of a substituent, or any other modification in the a or ω chain.
The nomenclature of the 15-keto-PG compounds used herein is based on the numbering system of the prostanoic acid represented in the above formula (A) .
A preferred compound used in the present invention is represented by the formula (I) :
[wherein x, W2 and W3 are carbon atom or oxygen atom, L, M and N are hydrogen, hydroxy, halogen, lower alkyl, hydroxy (lower) alkyl or oxo (wherein at least one of L and M is a group other than hydrogen, and the five-membered ring may have at least one double bond) ;
A is -CH2OH, -COCH2OH, -COOH or a functional derivative thereof;
B is -CH2-CH2-, -CH=CH- or -C≡C-;
R-L is a saturated or unsaturated bivalent lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted by halogen, alkyl, hydroxy, oxo, aryl or heterocyclic group; and
Ra is a saturated or unsaturated lower or medium aliphatic hydrocarbon residue, which is substituted at the end by cyclo (lower) alkyl, cyclo (lower) alkyloxy, aryl, aryloxy, heterocyclic group or hetrocyclic-oxy group.]
A group of particularly preferable compounds among the above-described compounds are represented by the formula (ID :
[wherein L and M are hydrogen, hydroxy, halogen, lower alkyl, hydroxy (lower) alkyl or oxo (wherein at least one of L and M is a group other than hydrogen, and the five-membered ring may have at least one double bond) ;
A is -CH2OH, -COCH2OH, -COOH or a functional derivative thereof;
B is -CH2-CH2-, -CH=CH-, -C≡C-;
X-L and X2 are hydrogen, lower alkyl, or halogen;
Rx is a saturated or unsaturated bivalent lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted with halogen, alkyl, hydroxy, oxo, aryl or heterocyclic group;
R2 is a single bond or lower alkylene; and
R3 is cyclo (lower) alkyl, cyclo (lower) alkyloxy, aryl, aryloxy, heterocyclic group or heterocyclic-oxy group.]
In the above formula, the term "unsaturated" in the definitions for Rx and Ra is intended to include at least one or more double bonds and/or triple bonds that are isolatedly, separately or serially present between carbon atoms of the main and/or side chains. According.to the usual nomenclature, an unsaturated bond between two serial positions is represented by denoting the lower number of the two positions, and an unsaturated bond between two distal positions is represented by denoting both of the positions.
The term "lower or medium aliphatic hydrocarbon" refers to a straight or branched chain hydrocarbon group having 1 to
14 carbon atoms (for a side chain, 1 to 3 carbon atoms are preferable) and preferably 1 to 10, especially 6 to 10 carbon atoms for Rx and 1 to 10, especially 1 to 8 carbon atoms for
Ra-
The term "halogen atom" covers fluorine, chlorine, bromine and iodine. The term "lower" throughout the specification is intended to include a group having 1 to 6 carbon atoms unless otherwise specified.
The term "lower alkyl" refers to a straight or branched chain saturated hydrocarbon group containing 1 to 6 carbon atoms and includes, for ex'ample, methyl, ethyl, propyl, isopropyl,
butyl, isobutyl, t-butyl, pentyl and hexyl .
The term "lower alkoxy" refers to a group of lower alkyl-O-, wherein lower alkyl is as defined above.
The term "hydroxy (lower) alkyl" refers to a lower alkyl as defined above which is substituted with at least one hydroxy group such as hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl and 1-methyl-l-hydroxyethyl.
The term "lower alkanoyloxy" refers to a group represented by the formula RCO-0-, wherein RCO- is an acyl group formed by oxidation of a lower alkyl group as defined above, such as acetyl.
The term "cyclo (lower) alkyl" refers to a cyclic group formed by cyclization of a lower alkyl group as defined above but contains three or more carbon atoms, and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
The term "cyclo (lower) alkyloxy" refers to the group of cyclo (lower) alkyl-O-, wherein cyclo (lower) alkyl is as defined above .
The term "aryl" may include unsubstituted or substituted aromatic hydrocarbon rings (preferably monocyclic groups) , for example, phenyl, tolyl, xylyl. Examples of the substituent include halogen atom and halo substituted (lower) alkyl, wherein halogen atom and lower alkyl are as defined above.
The term "aryloxy" refers to a group represented by the formula ArO-, wherein Ar is aryl as defined above.
The term "heterocyclic group" may include • mono- to tri-cyclic, preferably monocyclic heterocyclic group which is 5 to 14, preferably 5 to 10 membered ring having optionally substituted carbon atom(s) and 1 to 4, preferably 1 to 3 of 1 or 2 type of hetero atoms selected from nitrogen atom, oxygen atom and sulfer atom. Examples of the heterocyclic group include furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, furazanyl, pyranyl, pyridyl, pyridazinyl, pyrimidyl, pyrazinyl, 2-pyrrolinyl, pyrrolidinyl, 2-imidazolinyl, imidazolidinyl, 2-pyrazolinyl, pyrazolidinyl, piperidino, piperazinyl, morpholino, indolyl, benzothienyl, quinolyl, isoquinolyl, purinyl, quinazolinyl, carbazolyl, acridinyl, phenanthridinyl, benzi idazolyl, benzimidazolinyl, benzothiazolyl, phenothiazinyl. Examples of the substituent in this case include halogen, and halogen substituted lower alkyl group, wherein halogen atom and lower alkyl group are as described above.
The term "heterocyclic-oxy group" means a group represented by the formula HcO-, wherein He is a heterocyclic group as described above.
The term "functional derivative" of A includes salts (preferably pharmaceutically acceptable salts), ethers, esters and amides.
Suitable "pharmaceutically acceptable salts" include conventionally used non-toxic salts, for example a salt with
an inorganic base such as an alkali metal salt (such as sodium salt and potassium salt) , an alkaline earth metal salt (such as calcium salt and magnesium salt) , an ammonium salt; or a salt with an organic base, for example, an amine salt (such as methylamine salt, dimethylamine salt, cyclohexylamine salt, benzylamine salt, piperidine salt, ethylenediamine salt, ethanolamine salt, diethanolamine salt, triethanolamine salt, tris (hydroxymethylamino) ethane salt, monomethyl- monoethanolamine salt, lysine salt, procaine salt and caffeine salt) , a basic amino acid salt (such as arginine salt and lysine salt), tetraalkyl ammonium salt and the like. These salts may be prepared by a conventional process, for example from the corresponding acid and base or by salt interchange.
Examples of the ethers include alkyl ethers, for example, lower alkyl ethers such as methyl ether, ethyl ether, propyl ether, isopropyl ether, butyl ether, isobutyl ether, t-butyl ether, pentyl ether and 1-cyclopropyl ethyl ether; and medium or higher alkyl ethers such as octyl ether, diethylhexyl ether, lauryl ether and cetyl ether; unsaturated ethers such as oleyl ether and linolenyl ether; lower alkenyl ethers such as vinyl ether, allyl ether; lower alkynyl ethers such as ethynyl ether and propynyl ether; hydroxy (lower) alkyl ethers such as hydroxyethyl ether and hydroxyisopropyl ether; lower alkoxy (lower) alkyl ethers such as methoxymethyl ether and 1- methoxyethyl ether; optionally substituted aryl ethers such
as phenyl ether, tosyl ether, t-butylphenyl ether, salicyl ether, 3, 4-di-methoxyphenyl ether and benzamidophenyl ether; and aryl (lower) alkyl ethers such as benzyl ether, trityl ether and benzhydryl ether. Examples of the esters include aliphatic esters, for example, lower alkyl esters such as methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, t-butyl ester, pentyl ester and 1-cyclopropylethyl ester; lower alkenyl esters such as vinyl ester and allyl ester; lower alkynyl esters such as ethynyl ester and propynyl ester; hydroxy (lower) alkyl ester such as hydroxyethyl ester; lower alkoxy (lower) alkyl esters such as methoxymethyl ester and 1-methoxyethyl ester; and optionally substituted aryl esters such as, for example, phenyl ester, tolyl ester, t-butylphenyl ester, salicyl ester, 3, 4-di-methoxyphenyl ester and benzamidophenyl ester; and aryl (lower) alkyl ester such as benzyl ester, trityl ester and benzhydryl ester.
The amide of A means a group represented by the formula -CONR'R", wherein each of R' and R" is hydrogen atom, lower alkyl, aryl, alkyl- or aryl-sulfonyl, lower alkenyl and lower alkynyl, and include for example lower alkyl amides such as methylamide, ethylamide, dimethylamide and diethylamide; arylamides such as anilide and toluidide; and alkyl- or aryl-sulfonylamides such as methylsulfonyla ide, ethylsulfonyl-amide and tolylsulfonylamide.
Preferred examples of L and M include hydroxy which provides a 5-membered ring structure of, so called, PGF type.
Preferred A is -COOH, its pharmaceutically acceptable salt, ester or amide thereof.
5 Preferred B is -CH2-CH2-, which provide the structure of so-called, 13, 14-dihydro type.
Preferred example of Xx and X2 is that at least one of them is halogen, more preferably, both of them are halogen, especially, fluorine that provides a structure of, so called 10 16, 16-difluoro type.
Preferred Rλ is a hydrocarbon containing 1-10 carbon atoms, preferably, 6-10 carbon atoms.
Examples of Rx include, for example, the following groups: 15 —CH2—CH2 —CH2 _CH2-CH2—CH2—,
—CH2 _CH=CH—CH2~CH2~CH2—, —CH2—CH2~CH2—CH2~CH=CH—,
-CH2~C=C—CH2 —CH~CH->—,
— CH2— CH2~ CH2~ CH2 _ CH (CH ) — CH2— 2.0 — CH2— CH — CH2~ CH2 _ CH2— CH2— CH2— CH2— ,
— CH2— CH=CH— CH — CH2~ CH2— CH — CH2— , -CH2-CH2-CH2-CH2-CH2-CH2-CH=CH- ,
- CH2— C=C— CH2 — CH2 _ CH2~ CH2— CH — , -CH2-CH2-CH2-CH2-CH2-CH2-CH2 (CH3) -CH2-
25 Preferred Ra "is a hydrocarbon containing 1-10 carbon
atoms, more preferably, 1-8 carbon atoms which is substituted by aryl or aryloxy at the end.
The configuration of the ring and the - and/or ω chains in the above formula (I) and (II) may be the same as or different from that of the primary PGs. However, the present invention also includes a mixture of a compound having a primary type configuration and a compound of a non-primary type configuration.
The typical example of the compound used in the invention is a 13, 14-dihydro-15-keto-17-phenyl-18, 19, 20-trinor- prostaglandin F compound and its derivative or analogue.
The 15-keto-PG compound of the present invention may be in the keto-hemiacetal equilibrium by formation of a hemiacetal between hydroxy at position 11 and oxo at position 15. If such tautomeric isomers as above are present, the proportion of both tautomeric isomers varies with the structure of the rest of the molecule or the kind of the substituent present,. Sometimes one iso er may predominantly be present in comparison with the other. However, it is to be appreciated that the 15-keto-PG compounds used in the invention include both isomers . Further, while the compounds used in the invention may be represented by a structure formula or name based on keto-type regardless of the presence or absence of the isomers, it is to be noted that such structure or name does not intend to exclude the hemiacetal type compound.
In the present invention, any of isomers such as the individual tautomeric isomers, the mixture thereof, or optical isomers, the mixture thereof, a racemic mixture, and other steric isomers may be used in the same purpose. Some of the compounds used in the present invention may be prepared by the method disclosed in USP Nos. 5,073,569, 5,166,174, 5,221,763, 5,212,324, 5,739,161 and 6,242,485 (these cited references are herein incorporated by reference) . The term "treatment", "treat" or "treating" used herein includes any means of control such as prevention, care, relief of the condition, attenuation of the condition, arrest of progression of the condition.
The term "a subject in need of such treatment" means a subject who is suffering from a disease in which a reduction in his/her intraocular pressure is desirable, for example, glaucoma and ocular hypertension, or a subject who is susceptible to suffering from such disease as discussed above.
The subject may be any mammalian subject including human beings .
According to the present invention, the 15-keto-PG compound described as above may be formulated as an ophthalmic composition and applied topically to the eyes of a mammalian subject. The ophthalmic composition of the present invention may be any form for local eye administration used in the ophthalmic field such as eye drops and eye ointment. The ophthalmic composition may be prepared in a conventional manner
known to the art. The eye drops may be prepared by dissolving the active ingredients in a sterile aqueous solution such as saline and buffering solution, or the eye drop composition may be provided as a combined powder composition comprising the active ingredient to be dissolved in the aqueous solution before use .
Eye drops such as the ones as described in EP-A-0406791 are preferably used in the present invention (the cited reference is herein incorporated by reference) . If desired, additives ordinarily used in conventional eye drops may be added. Such additives may include isotonizing agents (e.g., sodium chloride), buffering agent (e.g., boric acid, sodium monohydrogen phosphate, sodium dihydrogen phosphate) , preservatives (e.g., benzalkonium chloride, benzethonium chloride, chlorobutanol) , thickeners (e.g., saccharide such as lactose, mannitol, maltose; hyaluronic acid or its salt such as sodium hyaluronate, potassium hyaluronate; mucopolysaccharide such as chondroitin sulfate; sodium polyacrylate, carboxyvinyl polymer, crosslinked polyacrylate.)
The eye drops may be formulated as a sterile unit dose type eye drops containing no preservatives.
Eye ointment may also be prepared in a conventional manner known to the art. For example, it may be prepared by mixing the active" ingredient into a base component
conventionally used for known eye ointments under a sterile condition. Examples of the base components for the eye ointment include petrolatum, selen 50, Plastibase and macrogol, but not limited thereto. Further, in order to increase the hydrophilicity, a surface-active agent can be added to the composition. The eye ointment may also contain the above- mentioned additives such as the preservatives and the like, if desired.
According to the present invention, more than 5μg and less than 50μg per eye of the above-defined 15-keto-compound is topically administered to the subject per administration. The dose of the 15-keto-compound is preferably less than 30μg, more preferably less than 20μg, further more preferably less than 15μg and still further preferably less than 12μg per eye per administration. The lower limit of the dose may be more than 7μg or more than lOμg per eye per administration.
The dose of the above-defined 15-keto-compound may vary within the range defined as above depending on the compound to be used, the type of subject such as animals or human, age, weight, symptom to be treated, desirable therapeutic effect, period for treatment and the like.
According to the invention, the frequency of the administration of the above-defined 15-keto-prostaglandin compound may vary depending on the compound to be used, the type of subject such as animals or human, age, weight, symptom to
be treated, desirable therapeutic effect, period for treatment and the like. The frequency of administration may be at least once a day and preferably, one to six times, more preferably, one to four times a day. Since the 15-keto-prostaglandin compound used in the invention causes substantially no or reduced ocular irritation even in a high dose, the treatment of the instant invention may be carried out for a long period of time.
The ophthalmic composition of the invention may contain a single active ingredient or a combination of two or more active ingredients. In a combination of plural active ingredients, their respective contents may be suitably increased or decreased in consideration of their therapeutic effects and safety. The concentration of the 15-keto-prostaglandin compound in the ophthalmic composition of the present invention is adjusted so that the amount of the compound to be administrated is within the range of more than 5μg and less than 50μg, preferably less than 30μg, more preferably less than 20μg, further more preferably less than 15μg and still further preferably less than 12μg per eye per administration. The lower limit of the amount may be more than 7μg or more than lOμg per eye per administration.
Further, the ophthalmic composition of the present invention may contain any other pharmaceutically active
ingredients as far as they are not contrary to the objects of the present invention.
Despite the high dose of the 15-keto-prostaglandin compound, a safe and comfortable treatment of ocular hypertension and glaucoma can be conducted for a long period of time according to the present invention. Besides, the present ophthalmic composition may be administered safely to subjects with ocular hypertension and glaucoma having some disorders on their cornea or conjunctiva such as allergic disease and dry eye.
The present invention will be described in more detail with reference to the following example, which is not intended to limit the present invention. EXAMPLE 1 The incidence rate of conjunctival hyperemia was compared between the present compound 13, 14-dihydro-15-keto- 17-phenyl-18, 19, 20-trinor-PGF2 a isopropyl ester and 13,14- dihydro-17-phenyl-18, 19, 20-trinor-PGF2o isopropyl ester. 1) Method Either 13, 14-dihydro-15-keto-17-phenyl-18, 19, 20- trinor-PGF2α isopropyl ester or 13, 14-dihydro-17-phenyl- 18, 19, 20-trinor-PGF2α isopropyl ester was ocularly administered once to one eye of white rabbits (three cases each, total of 12 cases) in a dose of 1.75μg or 50μg. 2) Evaluation Method
The presence of conjunctival hyperemia was examined at two hours after the administration and the ratio of cases showing conjunctival hyperemia was evaluated by percent in each group. 3) Results
Table 1 shows the results. Table 1
In the administration of 13, 14-dihydro-17-phenyl- 18, 19, 20-trinor-PGF2o isopropyl ester, 67% of the subjects receiving a clinical dose of 1.75μg and 100% of the subjects receiving 50μg showed conjunctival hyperemia.
On the other hand, in the administration of the present compound 13, 14-dihydro-15-keto-17-phenyl-18, 19, 20-trinor- PGF2α isopropyl ester, none of the subjects receiving the dose of 1.75μg showed conjunctival hyperemia. Even in the administration of a high dose of 50μg, the percent of the subjects showing conjunctival hyperemia was only about half the percent of the subjects receiving 1.75μg of 13, 14-dihydro- 17-phenyl-18, 19, 20-trinor-PGF2„ isopropyl ester.
EXAMPLE 2 Method
13,14-dihydro-15-keto-17-phenyl-18,19,20-trinor-PGF2Λ. isopropyl ester at a dose of 30 μg was ocularly administered to one eye of Dutch rabbits (4 male and 4 female, total 8 cases) . The administration was performed 4 times a day with 2-hour intervals for 13 weeks. The cornea, conjunctiva and iris were observed about occurrence of irritable response before, and 4, 8, and 13 weeks after the initiation of the administration. The observation was performed within the time from 0.5 hour to 2 hours after the last administration of the day. The cornea was observed about a presence of opacity and its area in the cornea. The conjunctiva was observed about occurrence of hyperemia, redness and swelling. The iris was observed about occurrence of hyperemia, congestion, swelling and hemorrhage. The ratio of cases showing irritable response in the cornea, conjunctiva or iris was evaluated by percent in the group. Results
As shown in Table 2 , the ocular administration of- 13, 14-dihydro-15-keto-17-phenyl-18, 19, 20-trinor-PGF2α isopropyl ester at a dose of 30 μg/eye each 4 times a day for 13 weeks had no effect on the cornea, conjunctiva and iris.
Table 2
These results demonstrate that the present compound causes substantially no or reduced ocular irritation even in a high dose. EXAMPLE 3 Method
13,14-dihydro-15-keto-17-phenyl-18,19,20-trinor-PGF2α isopropyl ester at a dose of 12 μg was ocularly administered to one eye (test eye) of 6 healthy volunteers. The vehicle solution was ocularly administered to the contralateral eye (control eye) . Intraocular pressure (IOP) was measured by means of an applanation tonometer before, and 4, 6, and 12 hours after the administration. The IOP lowering effect of the test compound was evaluated based on difference in IOP between test eye and the control eye at each time point of IOP measurement. Results
As shown in Table 3, the ocular administration of 13,14-dihydro-15-keto-17-phenyl-18,19,20-trinor-PGF2α isopropyl ester at a dose of 12 μg lowered the IOP by 1.0, 0.8 and 1.1 m Hg at 4, b, and 12 hours after the administration
respectively as compared with the control eye. Table 3
EXAMPLE 4 Method Nine male cynomolgus monkeys (body weights of animals ranged between 3.2 and 5.4 kg) without abnormalities in the anterior segment of the eye were used.
13,14-dihydro-15-keto-17-phenyl-18,19,20-trinor-PGF2α isopropyl ester at a dose of 15 μg/eye was administered topically to the right eyes of the animals at an administration volume of 30 μL/eye. The left eye received an equal volume of the vehicle.
Intraocular pressure (IOP) measurements were conducted by means of an applanation pneumatonometer (Model 30 Classic™, Mentor 0 & 0, Inc., USA) immediately before the administration
(0-hour), and at 2, 4, 8, 12, 24, 28, and 32 hours after the administration.
Eye irritancy as scored according to the criteria presented in Table 4 at the same time points as IOP measurements. These criteria are based on those of Draize test.
Table 4 : Scale for Scoring Ocular Lesions
1. Cornea
A. Opacity — Degree of Density (area which is most dense is taken for reading.) No opacity 0
Scattered or diffuse area — details of iris clearly visible 1
Easily discernible translucent areas, details of iris slightly obscured 2
Opalescent areas, no details of iris visible, size of pupil barely discernible... 3
Opaque, iris invisible ' 4 B. Area of Cornea Involved
One quarter (or less) but not zero 1
Greater than one quarter — less than one-half. 2
Greater than one-half less than three quarters 3
Greater than three quarters up to whole area 4 Score equals A X B X 5 Total maximum = 80
2. Iris
A. Values
Normal 0 Folds above normal, congestion, swelling, circumcorneal injection
(any one or all of these or combination of any thereof) 1
Hemorrhage; gross destruction (any one or both of these) 2
Score equals A X 5 Total maximum = 80 3. Conjunctivae
A. Redness (refers to palpebral conjunctivae only)
Normal 0
Vessels definitely injected above normal 1
More diffuse, deeper crimson red, individual vessels not easily discernible.. 2 Diffuse beefy red 3
B. Chemosis
No swelling 0
Any swelling above normal (includes nictitating membrane) 1 Obvious swelling with partial eversion of the lids 2
Swelling with lids about half closed 3
Swelling with lids about half closed to completely closed 4
C. Discharge No discharge 0
Any amount different from normal (does not include small amount observed in inner canthus of normal animals) 1
Discharge with moistening of the lids and hairs just adjacent to the lids 2
Discharge with moistening of the lids and considerable area around the eye.. 3 Score (A + B +C) X 2 Total maximum = 20
The maximum total score is the sum of all scores obtained for the cornea, iris and conjunctivae.
Results
As shown in Table 5, topical administration of 13,14- dihydro-15-keto-17-phenyl-18, 19, 20-trinor-PGF2α isopropyl ester at a dose of 15 μg/eye produced a significant IOP reduction. As shown in Table 6, no signs or symptoms of ocular irritation were observed after topical administration of 13,14-dihydro-15-keto-17-phenyl-18,19,20-trinor-PGF2α isopropyl ester.
These results demonstrate that the compound used in the invention shows IOP-lowering effect while causes substantially no or reduced ocular irritation even in a high dose.
Table 5.
Effects of 13, 14-dihydro-15-keto-17-phenyl-18, 19, 20-trinor-PGF2α isopropyl ester on IOP in monkey eyes
t
CTi
(paired Student's t-test) , #p < 0.01, #p < 0.05 compared to vehicle-treated contralateral eye (paired Wilcoxon's test)
Table 6. Evaluation for eye irritancy
IV>
Eye irritancy was scored according to the criteria presented in Table 4
Claims (20)
1. A method for treatment of ocular hypertension and glaucoma, which comprises administrating topically to the eyes of a mammalian subject in need of such treatment more than 5μg and less than 50μg per eye per administration of a 15-keto-prostaglandin compound having .a ring structure at the end of the ω chain.
2. The method as described in claim 1, wherein said 15- keto-prostaglandin compound is a compound represented by the following general formula (I) :
wherein Wx, W2 and W3 are carbon atom or oxygen atom, L, M and N are hydrogen, hydroxy, halogen, lower alkyl, hydroxy (lower) alkyl or oxo provided that at least one of L and M is a group other than hydrogen, and the five-membered ring may have at least one double bond;
A is -CH2OH, -COCH2OH, -COOH or a functional derivative thereof; B is -CH2-CH2-, -CH=CH- or -C≡C-; Rλ is a saturated or unsaturated bivalent lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted by halogen, alkyl, hydroxy, oxo, aryl or heterocyclic group; and Ra is a saturated or unsaturated lower or medium aliphatic hydrocarbon residue, which is substituted at the end by cyclo (lower) alkyl, cyclo (lower) alkyloxy, aryl, aryloxy, heterocyclic group or hetrocyclic-oxy group.
3. The method as described in claim 1, wherein said 15- keto-prostaglandin compound is a 13, 14-dihydro-15-keto- prostaglandin compound.
4. The method as described in claim 1, wherein said 15- keto-prostaglandin compound is a 13, 14-dihydro-15-keto-17- phenyl-18, 19, 20-trinor-prostaglandin compound.
5. The method as described any one of claims 1-4, wherein more than 5 μg and less than 30μg of said 15-keto- prostaglandin compound is administrated per eye per administratio .
6. The method as described in claim 5, wherein more than 5μg and less than 15μg of said 15-keto-prostaglandin compound is administrated per eye per administration.
7. An ophthalmic composition for treatment of ocular hypertension and glaucoma of a mammalian subject, which comprises a 15-keto-prostaglandin compound having a ring structure at the end of the ω chain in an amount to provide a dose of more than 5μg and less than 50μg per eye per administration.
8. The composition as described in claim 7, wherein said 15-keto-prostaglandin compound is a compound represented by the following general formula (I) :
wherein x, W2 and 3 are carbon atom or oxygen atom,
L, M and N are hydrogen, hydroxy, halogen, lower alkyl, hydroxy (lower) alkyl or oxo provided that at least one of L and M is a group other than hydrogen, and the five-membered ring may have at least one double bond;
A is -CH2OH, -COCH2OH, -COOH or a functional derivative thereof;
B is -CH2-CH2-, -CH=CH- or -G≡C-; R-L is a saturated or unsaturated bivalent lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted by halogen, alkyl, hydroxy, oxo, aryl or heterocyclic group; and
Ra is a saturated or unsaturated lower or medium aliphatic hydrocarbon residue, which is substituted at the end by cyclo (lower) alkyl, cyclo (lower) alkyloxy, aryl, aryloxy, heterocyclic group or hetrocyclic-oxy group.
9. The composition as described in claim 7, wherein said 15-keto-prostaglandin compound is a 13, 14-dihydro-15-keto- prostaglandin compound.
10. The composition as described in claim 7, wherein said 15-keto-prostaglandin compound is a 13, 14-dihydro-15-keto- 17-phenyl-18, 19, 20-trinor-prostaglandin compound.
11. The composition as described in any one of claims 7-10, wherein the dose is more than 5μg and less than 30μg per eye per administration.
12. The composition as described in claim 11, wherein the dose is more than 5μg and less than 15μg per eye per administration.
13. The composition as described in any one of claims 7-12, wherein the ophthalmic composition is an eye drop composition.
14. Use of a 15-keto-prostaglandin compound having a ring structure at the end of the ω chain for manufacturing an ophthalmic composition for treating ocular hypertension and glaucoma of a mammalian subject, wherein said composition comprises a 15-keto-prostaglandin compound in an amount to provide a dose of more than 5μg and less than 50μg per eye per administration.
15. The use as described in claim 14, wherein said 15- keto-prostaglandin compound is a compound represented by the following general formula (I) :
wherein Vllr W2 and W3 are carbon atom or oxygen atom, L, M and N are hydrogen, hydroxy, halogen, lower alkyl, hydroxy (lower) alkyl or oxo provided that at least one of L and M is a group other than hydrogen, and the five-membered ring may have at least one double bond;
A is -CH2OH, -COCH2OH, -COOH or a functional derivative thereof;
B is -CH2-CH2-, -CH=CH- or -C≡C-;
R-L is a saturated or unsaturated bivalent lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted by halogen, alkyl, hydroxy, oxo, aryl or heterocyclic group; and
Ra is a saturated or unsaturated lower or medium aliphatic hydrocarbon residue, which is substituted at the end by cyclo (lower) alkyl, cyclo (lower) alkyloxy, aryl, aryloxy, heterocyclic group or hetrocyclic-oxy group.
16. The use as described in claim 14, wherein said 15- keto-prostaglandin compound is a 13, 14-dihydro-15-keto- prostaglandin compound.
17. The use as described in claim 14, wherein said 15- keto-prostaglandin compound is a 13, 14-dihydro-15-keto-17- phenyl-18, 19, 20-trinor-prostaglandin compound.
18. The use as described in any one of claims 14-17, wherein the dose is. more than 5μg and less than 30μg per eye per administration.
19. The use as described in claim 18, wherein the dose is more than 5μg and less than 15μg per eye per administration,
20. The use as described in any one of claims 14-19, wherein the ophthalmic composition is an eye drop composition.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60/308,589 | 2001-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002355693A1 true AU2002355693A1 (en) | 2003-02-17 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012197308A (en) | Ophthalmic composition | |
US5208256A (en) | Treatment of ocular hypertension with a synergistic combination for ocular administration | |
EP2558103A1 (en) | Pharmaceutical composition for treating macular edema | |
US8609729B2 (en) | Method for treating macular degeneration | |
WO2003011299A2 (en) | Treatment of ocular hypertension and glaucoma | |
US20050014837A1 (en) | Method for treating ocular hypertension and glaucoma | |
US20030060511A1 (en) | Method for treatment of ocular hypertension and glaucoma | |
US20040254247A1 (en) | Method and composition for treatnment of ocular hypertension and glaucoma | |
AU2002355693A1 (en) | Treatment of ocular hypertension and glaucoma | |
US8853268B2 (en) | Ophthalmic solution | |
US20040225014A1 (en) | Method for treating ocular hypertension and glaucoma | |
US20040076678A1 (en) | Opthalmic solution | |
US20030220396A1 (en) | Method for treating ocular hypertension and glaucoma | |
AU2002255346A1 (en) | Method for treatingocular hypertension and glaucoma | |
AU2002326160A1 (en) | Method and composition for treatment of ocular hypertension and glaucoma |